Literature DB >> 12576228

Intravenous immunoglobulin modulates lymphocyte CD54 and monocyte FcgammaRII expression in patients with chronic inflammatory neuropathies.

A Créange1, N A Gregson, R A C Hughes.   

Abstract

We studied the expression of different lymphocyte and monocyte cellular determinants involved in leukodiapedesis and antigen presentation in 10 patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN) with persistent conduction blocks before intravenous immunoglobulin (IVIg), immediately after infusion of IVIg and 1 week after infusion. We observed a decrease of T lymphocytes expressing ICAM-1 (CD54) immediately after infusion in 8 out of 10 patients (p<0.04) with a return to pretreatment values after 1 week. The monocytes showed an increase in CD14(+) cells and CD14(+) FcgammaRII inhibitory receptor positive cells, no change in the number of CD14(+) FcgammaRIII activation receptor cells, and an increase in the FcgammaRII/FcgammaRIII ratio on monocytes 1 week after IVIg. Thus, the mechanism of action of IVIg in both CIDP and MMN may involve inhibition of T cell transmigration and modulation of antigen presentation capacities through FcgammaR expression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12576228     DOI: 10.1016/s0165-5728(02)00430-7

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  7 in total

Review 1.  Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors:  Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

2.  An update on the management of chronic inflammatory demyelinating polyneuropathy.

Authors:  Kenneth C Gorson
Journal:  Ther Adv Neurol Disord       Date:  2012-11       Impact factor: 6.570

3.  Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies.

Authors:  Saiju Jacob; Yusuf A Rajabally
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

Review 4.  Mechanistic effects of IVIg in neuroinflammatory diseases: conclusions based on clinicopathologic correlations.

Authors:  Marinos C Dalakas
Journal:  J Clin Immunol       Date:  2014-04-11       Impact factor: 8.317

Review 5.  The immune response and aging in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Kathleen M Hagen; Shalina S Ousman
Journal:  J Neuroinflammation       Date:  2021-03-22       Impact factor: 8.322

Review 6.  Human immune globulin infusion in the management of multifocal motor neuropathy.

Authors:  Elizabeth Jovanovich; Chafic Karam
Journal:  Degener Neurol Neuromuscul Dis       Date:  2015-12-22

Review 7.  Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy.

Authors:  Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2021-11-11       Impact factor: 7.620

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.